Cannabinoid and omega fatty acid compositions and methods of using
This disclosure describes compositions including cannabinoids and omega fatty acids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer therapeutic. In some aspects, the cannabinoid is chosen from i) CBC, CBCA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBL, CBLA, CBN, CBNA, THCV, THCVA, and any combination thereof, and ii) an approximately 1:1 equimolar mixture of CBD:CBDA. In some aspects, the omega fatty acid is chosen from an omega-3 fatty acid (such as ALA, DHA, or EPA), an omega-7 fatty acid, or an omega-9 fatty acid.
1 . A pill, comprising:
a cannabinoid component consisting essentially of an approximately 1:1 equimolar mixture of CBD: CBDA; and
an omega fatty acid component,
wherein the weight-to-weight ratio of the cannabinoid component to the omega fatty acid component ranges from approximately 1:1,250 to approximately 1:3,750.
2 . The pill of claim 1 , wherein the omega fatty acid component comprises an anti-inflammatory omega unsaturated fatty acid.
3 . The pill of claim 1 , wherein:
the omega fatty acid component comprises a plurality of omega fatty acids; and
a majority of the omega fatty acids of the plurality of omega fatty acids is docosahexaenoic acid (DHA).
4 . The pill of claim 1 , wherein:
the omega fatty acid component comprises a plurality of omega fatty acids; and
a majority of the omega fatty acids of the plurality of omega fatty acids is eicosapentaenoic acid (EPA).
5 . The pill of claim 1 , wherein:
the omega fatty acid component comprises a plurality of omega fatty acids; and
a majority of the plurality of omega fatty acids is a mixture of DHA and EPA.
6 . A method for at least one of reducing cytokine levels in vivo or in vitro or promoting antioxidant activity in a subject, comprising administering to the subject the pill of claim 1 .
7 . A method for treating or preventing cancer in a subject, comprising:
administering to the subject the pill of claim 1 ; and
administering an additional active agent to the subject, wherein the additional active agent comprises at least one of:
a chemotherapeutic agent;
a cytokine;
an antiviral agent;
an immune enhancer;
a tyrosine kinase inhibitor;
a protein kinase C (PKC) modulator;
a signal transduction inhibitor;
an antibiotic;
an antimicrobial agent;
a TLR agonist;
an inhibitor of IDO;
or an adjuvant.
8 . A pill, comprising:
a cannabinoid component consisting essentially of an approximately 1:1 equimolar mixture of CBD: CBDA; and
an omega fatty acid component consisting essentially of a mixture of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
wherein the weight-to-weight ratio of the cannabinoid component to the omega fatty acid component ranges from approximately 1:1,250 to approximately 1:3,750.
9 . The pill of claim 8 , further comprising a pharmaceutical carrier.
10 . A method of administering the pill of claim 8 , comprising administering an effective amount of the pill to a subject in need.
11 . The method of claim 10 , wherein the subject is a mammal.
12 . The method of claim 11 , wherein the mammal is a human.
13 . A method for inducing autophagy in a patient in need thereof comprising administering to the patient an effective amount of a pill comprising: i) an approximately 1:1 equimolar mixture of CBD: CBDA; and ii) an omega fatty acid, wherein the wherein the weight-to-weight ratio of the 1:1 equimolar mixture of CBD: CBDA to the omega fatty acid is approximately 1:375.
14 . The method of claim 13 , wherein the induction of the autophagy treats or prevents cancer and/or reduces inflammation in the patient.
15 . The pill of claim 1 , wherein the pill comprises from about 250 mg to about 1,500 mg of the omega fatty acid component.
16 . The pill of claim 1 , wherein the pill comprises from about 500 mg to about 1,000 mg of the omega fatty acid component.